Showing 8751-8760 of 10121 results for "".
- Evolus Acquires Exclusive US Distributor Rights to Evolysse Line of Dermal Fillershttps://practicaldermatology.com/news/evolus-acquires-exclusive-us-distributor-rights-to-evolysse-line-of-dermal-fillers/2461710/Evolus has entered into a definitive agreement to be the exclusive US distributor of a line of five dermal fillers currently in late-stage development. Evolus is partnering with Symatese, a privately held French company, to introduce the Evolysse line to its US customers beginning
- DermTech Appoints Bret Christensen as New President and CEOhttps://practicaldermatology.com/news/dermtech-appoints-bret-christensen-as-new-president-and-ceo/2461707/DermTech announced the appointment of Bret Christensen as president, chief executive officer, and a member of the board of directors. Mr. Christensen, who was previously chief commercial officer of Insulet, succeeds Dr. John Dobak, who stepped down as president, CEO and a dir
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Lilly's Lebrikizumab Improves AD on Face, Handshttps://practicaldermatology.com/news/lillys-lebrikizumab-improves-ad-on-face-hands/2461689/Up to 73% of atopic dermatitis patients (AD) receiving lebrikizumab showed Improved or cleared skin on face or hands at 16 weeks, a new study shows. Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 y
- Maintaining Normal Vitamin D Levels May Benefit Melanoma Patients on Immunotherapyhttps://practicaldermatology.com/news/maintaining-normal-vitamin-d-levels-may-benefit-melanoma-patients-on-immunotherapy/2461677/Patients with advanced skin cancer should make extra efforts to maintain normal vitamin D levels when receiving immune checkpoint inhibitors, according to a study in
- Green Living Environments Don't Protect Kids from Eczemahttps://practicaldermatology.com/news/green-living-environments-dont-protect-kids-from-eczema/2461675/Greenness or the significant presence of living vegetation around the home in early childhood does not seem to protect children from atopic eczema, a new Finnish study shows. Instead, the proximity of coniferous, mixed forests and agricultural areas was associated with elevated risk of
- Rodan + Fields Gives Back: Company Joins The Recycling Partnershiphttps://practicaldermatology.com/news/rodan-fields-gives-back-company-joins-the-recycling-partnership/2461673/Rodan + Fields, LLC. is joining 80 leading companies to support The Recycling Partnership, a nonprofit organization committed to building a better recycling system. Investing in The Recycling Partnership will help strengthen recycling access, education and infrastructure, advance
- News You Can Use: AARS Extends Deadline for Research Grant Applicationshttps://practicaldermatology.com/news/news-you-can-use-aars-extends-deadline-for-research-grant-applications-1/2461672/The American Acne and Rosacea Society is extending the deadline to apply for an AARS Clinical Research Award ($10K) or the AARS Research Scholar Award ($75K). The new application deadline is Friday, April 28, 2023. Applications are available online at acneandrosacea.org/
- Melanoma Research Alliance, Bimini Bay Outfitters Join Forces to Advance Researchhttps://practicaldermatology.com/news/melanoma-research-alliance-bimini-bay-outfitters-join-forces-to-advance-research/2461667/The Melanoma Research Alliance and Bimini Bay Outfitters, a leader in high-performance outdoor apparel, are partnering to accelerate research into melanoma and promote sun safety among outdoor enthusiasts. Alongside a series of educational content rolling out from both organizatio
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl